There seems to be quite a remarkable mismatch in valuation between Arovella Therapeutics and Chimeric, with ALA still in the pre-clinical phase compared to CHM with multiple platforms and clinical trials. Is their iNKT cell platform likely to be superior to CHMs core-NK platform in the long-run? If not, any comments on the valuation mismatch?
Questions for webinar, page-5
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable